OBJECTIVES:  To estimate efficiency of Remote Monitoring (Home Monitoring^TM, HM) of Cardiac Resyncronisation Therapy (CRT) and Implantable Cardioverter-Defibrillator (ICD) in Brazilian Public Healthcare System (SUS). METHODS: In patients with CRT/ICD therapy to treat heart failure (ICD-10 I50), continuous follow-up is based on outpatient visits (Conventional Follow-Up, CFU). HM is a new alternative which transmits real-time data to a central and then, to patient’s cardiologists. By means of a health-state transition model, incremental costs (in Brazilian currency, BRL) and efficacy (in life-years gained, LYG) were estimated in a time horizon of 10 years. Costs related to SUS were retrieved through Health Informatics Department of the Brazilian Ministry of Health (DATASUS). From patient-level data of IN-TIME study, a survival analysis (Exponential distribution) was run in order to predict risk of death across the years between CFU and HM groups. Probabilistic sensitivity analysis (PSA) and alternative scenarios were carried out to assess parametric and structural uncertainties. RESULTS: Base-case showed an incremental cost-effectiveness ratio (ICER) of BRL 2,599 per incremental LYG when HM and CFU are compared. PSA pointed out similar central point and indicates that thresholds over BRL 2,450 favours HM as the technology most efficient. As an alternative scenario, mortality was assumed to be the same for both groups. In this case, HM promotes an incremental cost of BRL 3,839 on average. Other alternative scenarios brought similar results. CONCLUSIONS: Discussing threshold in Brazil remains a controversial subject. Irrespective of this issue, economic evaluations are still useful to bring about additional information. In this view, HM is likely to promote additional direct costs and LYG. Compared to drugs, the cost of each additional benefit is much cheaper. In addition, this model is not sensitive to opportunity costs as less demand for cardiology outpatient clinics.